News | FDA | March 27, 2024

SyntheticMR announced today that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States

SyntheticMR announced today that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States

March 27, 2024 — SyntheticMR announced that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States. This milestone marks a significant advancement in quantitative MRI technology, offering unprecedented resolution and accuracy in brain imaging.

"We are thrilled to receive 510(k) clearance for SyMRI 3D," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, revolutionizing the landscape of medical diagnostics and offering new possibilities for diagnosis and treatment."

SyMRI 3D enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function. Furthermore, the resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions.

"Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging," says Jared Dixon, President of SyntheticMR U.S Inc.

With this clearance, SyntheticMR reaffirms its commitment to advancing medical imaging technology and providing clinicians with innovative tools to enhance patient care. SyMRI 3D opens up new possibilities for precise diagnosis, treatment planning, and monitoring, ultimately improving patient outcomes.

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-03-2024 11:01 CET.

For more information: www.syntheticmr.com

Related content:

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

Philips Teams with Synthetic MR to Deliver Breakthrough AI-based Quantitative Brain Imaging in MR to Advance Neurology Care for Patients at #ECR2024

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(k) Clearance


Related Content

News | Radiology Business

April 17, 2024 — VISTA.AI announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI ...

Time April 17, 2024
arrow
News | Radiology Business

April 4, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time April 04, 2024
arrow
News | Mammography

April 4, 2024 — Siemens Healthineers announces the Food and Drug Administration 510(k) clearance of the MAMMOMAT B ...

Time April 04, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a snapshot of the Top 10 most-read content from ITN's viewers during the month of March: 1. Philips Teams with ...

Time April 04, 2024
arrow
News | Radiology Imaging

April 3, 2024 — GE HealthCare announced the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology. The ...

Time April 03, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

March 27, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of the MAGNETOM Terra.X ...

Time March 27, 2024
arrow
News | FDA

March 21, 2024 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the CIARTIC Move ...

Time March 21, 2024
arrow
News | Artificial Intelligence

March 21, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time March 21, 2024
arrow
News | Artificial Intelligence

March 15, 2024 — Today, the U.S. Food and Drug Administration (FDA) released its “Artificial Intelligence and Medical ...

Time March 15, 2024
arrow
Subscribe Now